Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection.


Journal

Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857

Informations de publication

Date de publication:
03 2020
Historique:
received: 03 07 2019
revised: 24 12 2019
accepted: 23 01 2020
pubmed: 29 1 2020
medline: 22 6 2021
entrez: 29 1 2020
Statut: ppublish

Résumé

Acute-on-chronic liver failure (ACLF) is characterized by acute decompensation of cirrhosis (AD), organ failure(s) and high risk of short-term mortality with bacterial infection frequently as precipitating event. Innate immune pattern recognition receptors and members of the lectin pathway of complement activation are crucial to the innate immune response to pathogens. The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) of innate immune components are associated with the occurrence of bacterial infections or mortality in patients with cirrhosis hospitalized for AD or ACLF. Twenty-one innate immunity SNPs with known functional implications were genotyped in 826 AD/ACLF patients included in the CANONIC study. Associations between baseline characteristics of the patients, the occurrence of bacterial infections and survival rate at 90 days of follow-up in relation to the innate immunity genetic variants were analysed. The NOD2-G908R genetic variant was associated with mortality (HR 2.25, P = .004) independently of age and MELD Score. This association was also found in a predefined subgroup analysis in patients with bacterial infections (HR 2.78, P < .001) along with MBL_Yx (HR 1.72, P = .008) and MASP2_371 (HR 1.67, P = .012) genetic variants. None of the analysed SNPs were significantly associated with the occurrence of acute bacterial infections or spontaneous bacterial peritonitis in particular. Innate immune system-specific NOD2-G908R, MBL_Yx and MASP2_371 genetic variants were independently associated with increased risk of short-term mortality in AD/ACLF patients with bacterial infection.

Sections du résumé

BACKGROUND & AIMS
Acute-on-chronic liver failure (ACLF) is characterized by acute decompensation of cirrhosis (AD), organ failure(s) and high risk of short-term mortality with bacterial infection frequently as precipitating event. Innate immune pattern recognition receptors and members of the lectin pathway of complement activation are crucial to the innate immune response to pathogens. The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) of innate immune components are associated with the occurrence of bacterial infections or mortality in patients with cirrhosis hospitalized for AD or ACLF.
METHODS
Twenty-one innate immunity SNPs with known functional implications were genotyped in 826 AD/ACLF patients included in the CANONIC study. Associations between baseline characteristics of the patients, the occurrence of bacterial infections and survival rate at 90 days of follow-up in relation to the innate immunity genetic variants were analysed.
RESULTS
The NOD2-G908R genetic variant was associated with mortality (HR 2.25, P = .004) independently of age and MELD Score. This association was also found in a predefined subgroup analysis in patients with bacterial infections (HR 2.78, P < .001) along with MBL_Yx (HR 1.72, P = .008) and MASP2_371 (HR 1.67, P = .012) genetic variants. None of the analysed SNPs were significantly associated with the occurrence of acute bacterial infections or spontaneous bacterial peritonitis in particular.
CONCLUSIONS
Innate immune system-specific NOD2-G908R, MBL_Yx and MASP2_371 genetic variants were independently associated with increased risk of short-term mortality in AD/ACLF patients with bacterial infection.

Identifiants

pubmed: 31991025
doi: 10.1111/liv.14392
pmc: PMC7079071
doi:

Substances chimiques

NOD2 protein, human 0
Nod2 Signaling Adaptor Protein 0
MASP2 protein, human EC 3.4.21.-
Mannose-Binding Protein-Associated Serine Proteases EC 3.4.21.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

646-653

Informations de copyright

© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.

Références

Hepatology. 2010 Sep;52(3):1100-10
pubmed: 20593422
Expert Rev Gastroenterol Hepatol. 2018 Jul;12(7):641-656
pubmed: 29806487
Liver Int. 2017 Jul;37(7):1023-1031
pubmed: 28109038
J Hepatol. 2010 Sep;53(3):484-91
pubmed: 20605050
J Hepatol. 2015 Nov;63(5):1272-84
pubmed: 26192220
Liver Int. 2013 Jan;33(1):31-9
pubmed: 23121656
J Hepatol. 2014 Nov;61(5):1038-47
pubmed: 24950482
Gut. 2018 Oct;67(10):1870-1880
pubmed: 28847867
Liver Int. 2020 Mar;40(3):646-653
pubmed: 31991025
Infect Immun. 1979 Feb;23(2):403-11
pubmed: 154474
Dig Dis Sci. 2016 Jun;61(6):1545-52
pubmed: 26725065
PLoS One. 2013 Aug 19;8(8):e72617
pubmed: 23977330
Clin Transl Gastroenterol. 2019 Jan;10(1):e00002
pubmed: 30702490
J Exp Med. 1992 Dec 1;176(6):1497-502
pubmed: 1460414
Lancet. 1995 Apr 8;345(8954):886-9
pubmed: 7707811
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Hepatology. 2010 Apr;51(4):1327-33
pubmed: 20087966
Int J Biochem Cell Biol. 2011 May;43(5):705-12
pubmed: 21315829
Liver Int. 2018 Jul;38(7):1242-1252
pubmed: 29235260
JAMA. 2001 Mar 14;285(10):1316-21
pubmed: 11255386
Gastroenterology. 2005 Aug;129(2):408-14
pubmed: 16083697
Liver Int. 2012 Feb;32(2):223-30
pubmed: 21745302
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Hepatology. 2005 Mar;41(3):422-33
pubmed: 15723320
J Hepatol. 2011 Oct;55(4):800-7
pubmed: 21334396
J Immunol. 2000 Mar 1;164(5):2281-4
pubmed: 10679061
Lancet. 1995 Oct 7;346(8980):941-3
pubmed: 7564730
Dig Dis Sci. 2016 Jul;61(7):2142-4
pubmed: 27052012

Auteurs

Jelte J Schaapman (JJ)

Leiden University Medical Center, Leiden, The Netherlands.

Àlex Amoros (À)

European Foundation for the study of Chronic Liver Failure, Barcelona, Spain.

Johan J van der Reijden (JJ)

Leiden University Medical Center, Leiden, The Netherlands.

Wim Laleman (W)

UZ Leuven, Leuven, Belgium.

Stefan Zeuzem (S)

Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.

Rafael Bañares (R)

Gregorio Marañón Hospital, Madrid, Spain.

Rajiv Jalan (R)

University College London, Royal Free Hospital, London, UK.

Vicente Arroyo (V)

European Foundation for the study of Chronic Liver Failure, Barcelona, Spain.

Joan Clària (J)

European Foundation for the study of Chronic Liver Failure, Barcelona, Spain.
Hospital Clínic, IDIBAPS and CIBERehd, Barcelona, Spain.

Hein W Verspaget (HW)

Leiden University Medical Center, Leiden, The Netherlands.

Minneke J Coenraad (MJ)

Leiden University Medical Center, Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH